Stockscreener 앱 받기
0.90%
시간 외 거래:
전일 마감가:
$283.78
열려 있는:
$291.5
하루 거래량:
4.54M
Relative Volume:
1.50
시가총액:
$152.45B
수익:
$33.42B
순이익/손실:
$4.09B
주가수익비율:
37.25
EPS:
7.55
순현금흐름:
$10.39B
1주 성능:
+0.14%
1개월 성능:
-8.01%
6개월 성능:
-11.90%
1년 성능:
+1.02%
1일 변동 폭
$275.19
$291.61
1주일 범위
$275.19
$292.00
52주 변동 폭
$253.30
$346.85
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
281.22 | 152.45B | 33.42B | 4.09B | 10.39B | 7.55 |
|
LLY
Lilly Eli Co
|
823.62 | 713.24B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
156.12 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
198.47 | 329.14B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.23 | 275.58B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
114.29 | 221.49B | 53.22B | 12.86B | 14.85B | 6.39 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen Inc. Reports Strong Growth Amid Challenges - TipRanks
Amgen (AMGN) Receives a Revised Price Target from UBS Analyst | - GuruFocus
Robots of Amgen - Amgen
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data - Benzinga
Amgen (AMGN): RBC Capital Maintains Rating, Lowers Price Target | AMGN Stock News - GuruFocus
Amgen (NasdaqGS:AMGN) Reports Strong Q1 Earnings With Revenue Increase To US$8 Billion - simplywall.st
Amgen’s Stelara biosimilar gets off to fast start - BioPharma Dive
Citigroup Adjusts Price Target on Amgen to $300 From $290 - marketscreener.com
Cantor Fitzgerald maintains neutral on Amgen stock, target at $305 By Investing.com - Investing.com UK
Amgen Unusual Options Activity For May 02 - Nasdaq
Amgen (AMGN) Price Target Reduced by UBS Analyst | AMGN Stock News - GuruFocus
Amgen (AMGN) Surges After Beating Q1 Earnings Expectations - GuruFocus
Strong first-quarter product sales for Amgen - The Pharma Letter
Bison Wealth LLC Sells 3,130 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Parvin Asset Management LLC Invests $1.46 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Street View: Investor focus still on Amgen's weight-loss drug candidate - TradingView
UBS Adjusts Price Target on Amgen to $315 From $319, Maintains Neutral Rating - marketscreener.com
Navigoe LLC Makes New $390,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth - TradingView
Comerica Bank Reduces Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bridgewealth Advisory Group LLC Makes New $417,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Becker Capital Management Inc. Reduces Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
RBC Trims Price Target on Amgen to $320 From $324, Keeps Outperform Rating - marketscreener.com
PDT Partners LLC Has $1.51 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition - insights.citeline.com
Amgen Inc (AMGN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Pricing Challenges - Yahoo Finance
Nebula Research & Development LLC Acquires Shares of 4,531 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Oxford Asset Management LLP Takes $1.25 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Swings To Q1 Profit, Beats Street View; Guides FY25 - Nasdaq
Amgen Reports Strong Q1 2025 Financial Results - TipRanks
Amgen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Spotlight On: Amgen pins hopes on cardiometabolic pipeline - FirstWord Pharma
Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts - insights.citeline.com
Amgen posts profit, says tax policy more effective than tariffs - Reuters
Amgen signals strong 2025 outlook with revenue growth and pipeline advancements - MSN
Amgen (AMGN) Reports Strong Q1 2025 Results with Positive Revenue Growth - GuruFocus
Amgen Q1 Adjusted EPS $4.90 Vs IBES Estimate $4.30 - marketscreener.com
Earnings call transcript: Amgen beats Q1 2025 earnings expectations, stock declines - Investing.com
Amgen (AMGN) Surpasses Expectations with Strong Q1 Performance - GuruFocus
Amgen beats on both lines and reaffirms guidance; stock flat post market - MSN
Amgen Grows Profits And Stays On Track With New Drug Developments - Finimize
Amgen Inc (AMGN) Q1 2025 Earnings: GAAP EPS of $3.20 Beats Estim - GuruFocus
Amgen (AMGN) Surpasses Q1 Expectations, Sets 2025 Guidance - GuruFocus
Amgen (AMGN) Exceeds Q1 Expectations, Maintains FY25 Forecast - GuruFocus
Amgen Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMGN) - Seeking Alpha
Amgen Q1 2025 slides: Revenue up 9%, EPS jumps 24% as pipeline advances - Investing.com India
Highlights from Amgen’s 2025 First Quarter Earnings Report - Amgen
Amgen in charts: XGEVA sales reach $566M in Q1 (AMGN:NASDAQ) - Seeking Alpha
Amgen quarterly profit tops Wall Street view, sales up 11% - MSN
Amgen Beats on Profit as Obesity Drug Moves Toward Market - MSN
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.13%
0.10%
자본화:
|
볼륨(24시간):